Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555744 · ClinicalTrials.gov registry record · Phase 1
A Study of ZW191 in Participants With Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Zymeworks BC.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT06555744: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Zymeworks BC.
NCT06555744 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Zymeworks BC. The registered enrollment target is 145 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06555744, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Zymeworks BC.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Primary Outcome
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW191
Conditions Studied
Interventions
- DRUG ZW191
Study Locations (20)
Other
- Linear Clinical Research - Nedlands
- Royal North Shore Hospital Northern Sydney Cancer Centre - St Leonards
- National Cancer Center Hospital East - Kashiwa-shi
- Saitama Medical University International Medical Center - Saitama
- National Cancer Center Hospital - Tokyo
- The Cancer Institute Hospital of JFCR - Tokyo
- National University Health System (NUHS) - National University Cancer Institute Singapore (NCIS) - Singapore
- National Cancer Centre Singapore - Singapore
- Curie Oncology - Singapore
- National Cancer Center - Goyang-si
- Seoul National University Bundang Hospital - Seongnam-si
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
Connecticut
- Yale University - New Haven
Ohio
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute - Columbus
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Texas
- NEXT Oncology - San Antonio
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT06555744 shows while recruiting
NCT06555744 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ZW191 is the first listed.
NCT06555744 names 20 study sites across 6 states, led by Other, Connecticut, Ohio.
Frequently Asked Questions
What is clinical trial NCT06555744 about?
NCT06555744 is a clinical study titled "A Study of ZW191 in Participants With Solid Tumors". The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
What is the current status of trial NCT06555744?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2024-10-30. Estimated completion is 2027-01.
What conditions does trial NCT06555744 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06555744?
The interventions under investigation include: ZW191 (DRUG).
Who is sponsoring clinical trial NCT06555744?
This trial is sponsored by Zymeworks BC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555744 being conducted?
This trial has 20 study locations across Connecticut, Ohio, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06555744's enrollment target sits among peer trials
145 61st of 144 higher than 84 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI